[Skip to Navigation]
Sign In
Comment & Response
May 20, 2021

Universal Genetic Testing to Identify Pathogenic Germline Variants in Patients With Cancer

Author Affiliations
  • 1Department of Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina
JAMA Oncol. 2021;7(7):1070. doi:10.1001/jamaoncol.2021.1002

To the Editor In their recent multicenter cohort study published in JAMA Oncology, Samadder et al1 found that 13.3% (397 of 2984) of patients diagnosed with cancer harbored a pathogenic germline variant (PGV) and that 71.0% (282 of 397) of these PGVs were either high or moderate penetrance. They report that treatment decisions were commonly based on those discovered PGVs.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words